BRIM plans to launch a new funding round to accelerate late-stage clinical trial and initiate a new phase 2 trial for orphan drug BRM424 in the U.S
Taipei, Taiwan, 10th May, 2023, BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint diseases, announced today that the Board of Directors has approved a seasoned equity offering that…
BRM421, a new drug for treating Dry Eye Disease, receives approval to proceed to Phase 2 clinical trials in China
Taipei, Taiwan, 18th Apr 18, 2023, BRIM Biotechnology, Inc. (“BRIM”, TPEx 6885) announced that BRM421 for the treatment of dry eye disease, licensed out to Grand Pharmaceutical Group Limited (Grand Pharmaceutical) for the China region, has been approved by the…
BRIM submits US IND for BRM424 Phase 2 study treating neurotrophic keratitis
Taipei, Taiwan, 6th April 2023, BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative peptide therapies, submitted IND today for BRM424, which received ODD status from the FDA last November. If no comment from the FDA is…
BRIM Biotechnology announces first patient enrollment in pivotal Phase 3 clinical trial of BRM421 for Dry Eye Disease
Taipei, Taiwan, 2nd March 2023 / BRIM Biotechnology Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that the first patient has been enrolled in its Phase 3 clinical…
Novel regenerative peptide therapy for dry eye disease, BRM421, advances to Phase 3 clinical trials
There is currently no cure for Dry Eye Disease. Existing treatments are often not enough to control discomfort for moderate to severe patients unless there is a way to further speed up the healing process. Through its multi-modal mechanism of…
BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead
BRIM’s new Board of Directors elects Andrew Lin as the new Chairman of the Board and appoints Dr. Wen-Chyi Shyu as the new CEO Taipei, Taiwan, February 20th, 2023 / BRIM Biotechnology, Inc. (BRIM, TPEx 6885), a clinical-stage company developing novel regenerative therapies…
BRIM Biotechnology receives FDA Orphan Drug Designation for BRM424 to treat neurotrophic keratitis
Taipei, Taiwan, 8th December 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye…
BRIM Biotechnology, Inc. raises $20 million in Series E funding round
Taipei, Taiwan, 1st December 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E funding…
BRIM Biotech submits US Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease to the FDA
Taipei, Taiwan, Nov 16th, 2022, BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration…
BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting
Taipei, Taiwan, 1st November, 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate…